Sanjay S. Shukla, M.D., M.S. President, Chief Executive Officer and Director September 11, 2026

filing / Sep 11, 2026 / receipt

In connection with the Restructuring Plan, we committed to a reduction in our total workforce by approximately 60% to 20 full-time employees, and we estimate that the Restructuring Plan will reduce annualized operating expenses by approximately $13 million, beginning in the fourth quarter of 2026.

filing / Aug 7, 2026 / receipt

On August 7, 2026, our board of directors approved the implementation of a corporate restructuring and program prioritization plan (the Restructuring Plan) to streamline our operations, and conserve capital prior to the potential initiation of the Planned Phase 3 Study.

filing / Aug 7, 2026 / receipt

On August 7, 2026, our board of directors appointed Brandon Yaras, our Vice President, Finance, to succeed Ms. Broadfoot as our Chief Financial Officer and designated him as our “principal financial officer” and “principal accounting officer,” each within the meaning of Rule 16a-1(f) under the Exchange Act, all effective as of October 1, 2026.

filing / Aug 7, 2026 / receipt

Yaras and any other person pursuant to which he was appointed as our Chief Financial Officer, and there are no actual or proposed transactions between us and Mr.

filing / Aug 7, 2026 / receipt

There can be no assurance that any restructuring activities that we have undertaken or undertake in the future will achieve the cost savings, operating efficiencies or other benefits that we may initially expect.

filing / Aug 7, 2026 / receipt

There can be no assurance that any restructuring activities that we have undertaken or undertake in the future will achieve the cost savings, operating efficiencies or other benefits that we may initially expect.

filing / May 15, 2026 / receipt